Dawnrays Pharmaceutical Holdings Ltd. (HK:2348)
:2348
Want to see HK:2348 full AI Analyst Report?
Top Page
Dawnrays Pharmaceutical Holdings Ltd.
(2348)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$1.00
▼(-16.67% Downside)
Action:ReiteratedDate:04/25/26
The score is primarily supported by a very strong, low-leverage balance sheet and attractive valuation (low P/E and high dividend yield). Offsetting these positives are uneven earnings/cash-flow reliability and a weak-to-neutral technical setup with price below longer-term moving averages.
Positive Factors
Low Leverage & Strong Equity
Extremely low debt and a large equity base give durable financial flexibility: the company can fund R&D, capex, dividends or opportunistic M&A without high interest burden. This conservatism reduces refinancing risk and supports operations through multi-quarter industry cycles.
Negative Factors
Earnings Volatility
A large year‑over‑year earnings swing highlights unstable profitability drivers such as product mix, one‑offs or margin pressure. Persistent earnings volatility complicates forecasting, capital allocation and could constrain sustained investment or dividend commitments over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage & Strong Equity
Extremely low debt and a large equity base give durable financial flexibility: the company can fund R&D, capex, dividends or opportunistic M&A without high interest burden. This conservatism reduces refinancing risk and supports operations through multi-quarter industry cycles.
Read all positive factors
Dawnrays Pharmaceutical Holdings Ltd. (2348) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.70B
Dividend Yield5.16%
Average Volume (3M)355.07K
Price to Earnings (P/E)7.9
Beta (1Y)0.30
Revenue Growth16.09%
EPS Growth-62.16%
CountryHK
Employees1,183
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.08
Shares Outstanding1,503,605,000
10 Day Avg. Volume239,600
30 Day Avg. Volume355,066
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.49
Price to Sales (P/S)1.37
P/FCF Ratio6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Dawnrays Pharmaceutical Holdings Ltd. Business Overview & Revenue Model
Company Description
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines...
How the Company Makes Money
The company primarily makes money by generating revenue from the sale of pharmaceutical products it manufactures and commercializes, including revenue earned through distribution and sales channels to hospitals, pharmacies, and other healthcare cu...
Dawnrays Pharmaceutical Holdings Ltd. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
68
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.20B | 1.06B | 1.15B | 1.28B | 1.17B |
| Gross Profit | 593.41M | 577.63M | 641.52M | 766.68M | 675.36M |
| EBITDA | 311.21M | 280.49M | 498.94M | 505.19M | 433.89M |
| Net Income | 208.43M | 564.94M | 326.00M | 358.06M | 358.18M |
Balance Sheet | |||||
| Total Assets | 4.01B | 4.01B | 3.62B | 3.67B | 3.34B |
| Cash, Cash Equivalents and Short-Term Investments | 1.58B | 1.37B | 1.07B | 993.04M | 830.22M |
| Total Debt | 77.51M | 34.72M | 120.53M | 8.41M | 23.52M |
| Total Liabilities | 621.75M | 682.61M | 763.42M | 1.02B | 941.70M |
| Stockholders Equity | 3.39B | 3.32B | 2.85B | 2.64B | 2.38B |
Cash Flow | |||||
| Free Cash Flow | 236.01M | 44.58M | 126.39M | 229.90M | 80.07M |
| Operating Cash Flow | 355.41M | 220.20M | 338.40M | 434.27M | 393.14M |
| Investing Cash Flow | -368.80M | 205.17M | -387.57M | -175.01M | -284.20M |
| Financing Cash Flow | -54.99M | -189.44M | 2.07M | -92.70M | -129.75M |
Dawnrays Pharmaceutical Holdings Ltd. Technical Analysis
Negative
1.20
Price Trends
1.15
Negative
1.18
Negative
1.21
Negative
Market Momentum
>-0.01
Negative
44.74
Neutral
42.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2348, the sentiment is Negative. The current price of 1.2 is above the 20-day moving average (MA) of 1.12, above the 50-day MA of 1.15, and below the 200-day MA of 1.21, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.74 is Neutral, neither overbought nor oversold. The STOCH value of 42.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2348.
Dawnrays Pharmaceutical Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$7.31B | 6.31 | 11.90% | 5.80% | -17.03% | 12.82% | |
72 Outperform | HK$1.70B | 7.90 | 6.34% | 5.16% | 16.09% | -62.16% | |
72 Outperform | HK$12.93B | 11.34 | 24.04% | 3.93% | 15.28% | 14.76% | |
69 Neutral | HK$2.17B | 5.13 | 12.91% | 15.40% | -1.88% | 17.57% | |
54 Neutral | HK$8.61B | -28.37 | -1.64% | 3.66% | -10.68% | -737.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$12.32B | 34.17 | 3.49% | 0.87% | 37.90% | ― |
* Healthcare Sector Average
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.14
0.07
6.54%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.67
-0.26
-13.61%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.31
0.59
80.94%
HK:1681
Consun Pharmaceutical Group Ltd.
16.11
7.05
77.89%
HK:2633
Jacobson Pharma Corporation Limited
1.13
<0.01
0.89%
HK:2877
China Shineway Pharmaceutical Group Limited
9.78
2.58
35.83%
Dawnrays Pharmaceutical Holdings Ltd. Corporate Events
Dawnrays Pharmaceutical Calls 2026 AGM, Proposes Dividend and Share Issue Mandate
Apr 23, 2026
Dawnrays Pharmaceutical (Holdings) Limited has called its Annual General Meeting for 22 May 2026 in Hong Kong, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed final dividen...
Dawnrays Pharmaceutical Sees Core Earnings Edge Up as One-Off Gains Drop Off
Mar 27, 2026
Dawnrays Pharmaceutical reported 2025 revenue of RMB1.23 billion, up 16.1% year on year, with gross profit rising 6% to RMB612.2 million but gross margin narrowing to 49.7%. Profit attributable to shareholders dropped 62.1% to RMB214.0 million, as...
Dawnrays Pharmaceutical Announces Final Dividend for FY2025 and Key Dates
Mar 27, 2026
Dawnrays Pharmaceutical (Holdings) Ltd. has declared a final ordinary dividend of HKD 0.048 per share for the financial year ended 31 December 2025, subject to shareholder approval at the annual general meeting on 22 May 2026. The company has set ...
Dawnrays Pharma Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 13, 2026
Dawnrays Pharmaceutical (Holdings) Limited has scheduled a board meeting for 27 March 2026 to review and approve the audited annual results of the company and its subsidiaries for the financial year ended 31 December 2025. At the same meeting, the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.